Raf

Inhibitors

Cat.No.	Name	Information
M1988	Dabrafenib	Dabrafenib (free base) (GSK2118436A) is a V600 mutant BRAF-specific inhibitor.
M3026	Sorafenib (BAY 43-9006)	Sorafenib (BAY 43-9006) is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM, respectively.
M1774	PLX-4720	PLX-4720 is a selective BRAFV600E inhibitor with the IC50 values of 160 nM and 130 nM for B-Raf and BRK respectively.
M1761	Vemurafenib (PLX4032)	Vemurafenib (PLX4032) is the first and effective selective inhibitor of B-Raf, which can inhibit RAFV600E and C-RAF-1 activity with IC50 of 31 nM and 48 nM, respectively. Vemurafenib induces autophagy.
M2319	AZ628	AZ628 is a potent inhibitor for wild-type CRAF and BRAF V600E with IC50 of 29 nM and 34 nM, respectively.
M21520	Vemurafenib-d5	Vemurafenib (PLX4032; RG7204; RO5185426) is a first-in-class selective B-RAF inhibitor that inhibits the activity of RAFV600E and c-RAF-1 with IC50 at 31 nM and 48 nM, respectively.
M21513	Vemurafenib-d7	Vemurafenib (PLX4032; RG7204; RO5185426) is a first-in-class selective B-RAF inhibitor that inhibits the activity of RAFV600E and c-RAF-1 with IC50 at 31 nM and 48 nM, respectively. Vemurafenib can induce autophagy.
M21146	LUT014	LUT014, a B-Raf inhibitor with an IC50 value of 11.7 nM, was developed for the study of reducing acne-like lesions associated with EGFR inhibitors at restricted doses.
M21135	GNE-9815	GNE-9815 is one of the most selective kinase inhibitors of RAF, targeting KRAS mutant cancers by combination of drugs.
M20688	B-Raf inhibitor 1 (Compound 13) dihydrochloride	B-Raf inhibitor 1 (Compound 13) is a type IIA Raf inhibitor which bind to the DFG-out conformation with ki of 1 nM,1 nM,and 0.3 nM for B-Raf(WT), B-Raf(V600E) and C-Raf, respectively.
M20678	Belvarafenib (GDC5573, HM95573, RG6185)	Belvarafenib (GDC5573, HM95573, RG6185) is a selective and orally bioavailable pan-RAF kinase inhibitor with IC50 values of 41 nM, 7 nM and 2 nM for BRAF WT, BRAF(V600E) and CRAF kinases, respectively.
M20609	CCT196969	CCT196969 is a novel orally available, pan-RAF inhibitor with anti-SRC activity. It also inhibits SRC, LCK, and the p38 MAPKs.
M20334	WAY-303292	WAY-303292 is a inhibitor of B-Raf kinase.
M20274	WAY-655860	WAY-655860 is a inhibitor of B-Raf.
M20242	WAY-635114	WAY-635114 is a inhibitor of B-Raf kinase.
M20241	WAY-635109	WAY-635109 is a inhibitor of B-Raf kinase.
M20075	WAY-310819	WAY-310819 is a B-Raf inhibitor
M14181	LY3009120	LY3009120 (DP-4978) is a pan RAF inhibitor which inhibits BRAF^V600E, BRAF^WT and CRAF^WT with IC50s of 5.8, 9.1 and 15 nM, respectively.
M10591	AZ304	AZ304 is a potent dual BRAF inhibitor targeting the kinase domains of wild type BRAF, V600E mutant BRAF with IC50 values of 79 nM and 38 nM respectively.
M10475	Lifirafenib (BGB-283)	Lifirafenib (BGB-283) is a novel potent and selective RAF Kinase and EGFR inhibitor with IC50 values of 23, 29 and 495 nM for the recombinant BRAFV600E kinase domain, EGFR and EGFR T790M/L858R mutant.
M10438	BI 882370	BI 882370 is a highly potent and selective RAF inhibitor that binds to the DFG-out (inactive) conformation of the BRAF kinase.
M10152	Naporafenib	Naporafenib (also known as LXH254) is an orally available inhibitor of C-Raf and B-Raf with potential antineoplastic activity.
M9492	B-Raf inhibitor 1	B-Raf inhibitor 1 is a potent and selective B-Raf inhibitor with cell IC50s of 0.31 µM and 2 nM for A375 proliferation and A375 p-ERK, respectively.
M9008	PLX7904	PLX7904, also known as PB04, is a potent and selective paradox-breaker RAF inhibitor.
M9007	PLX8394	PLX8394 is an orally bioavailable, potent and selective Raf inhibitor with IC50 of 5 nM.

Signaling Pathways

Product Type

Raf

Get to Know Us

Customer Support

Resources

Contact Us